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5 Clinical prediction rulesDiagnostic Test Evaluation
1 The performance of a diagnostic test assessed by comparison
of index and reference test results on a group of subjects
2 Ideally these should be patients suspected of the target
condition that the test is designed to detect.
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Test Positive True Positive False Positive
Test Negative False Negative True NegativeMeasures of Diagnostic Performance
Sensitivity (true positive rate) The proportion of people with
disease who are correctly identiﬁed
as such by test
Speciﬁcity (true negative rate) The proportion of people without
disease who are correctly identiﬁed
as such by test
Positive predictive value The proportion of test positive
people who truly have disease
Negative predictive value The proportion of test negative
people who truly do not have
diseaseMeasures of Diagnostic Performance
Likelihood ratios (LR) The ratio of the probability of a positive (or
negative) test result in the patients with
disease to the probability of the same test
result in the patients without the disease
Diagnostic odds ratio The ratio of the odds of a positive test
result in patients with disease compared to
the odds of the same test result in patients
without disease.
ROC Curve Plot of all pairs of (1-speciﬁcity, sensitivity)
as positivity threshold variesMeta-analysis of Diagnostic Performance
Rationale
1 Evaluation of the quality and scope of available primary
studies
2 Determination of the proper and eﬃcacious use of diagnostic
and screening tests in the clinical setting in order to guide
patient treatment
3 Decision making about health care policy and ﬁnancing
4 Identiﬁcation of areas for further research, development, and
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Major steps
1 Framing objectives of the review
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3 Assessment of methodological quality and applicability to the
clinical problem at hand
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Depends on presence, extent and sources of variability due to:
1 Methodological quality bias
2 Covariate Heterogeneity
3 Publication and other sample size-related bias
4 Threshold Eﬀects
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5 Unobserved heterogeneityExtent of Heterogeneity
1 Assessed statistically using the quantity I2 described by
Higgins and Colleagues (2002).
2 Deﬁned as percentage of total variation across studies
attributable to heterogeneity rather than chance.
3 I2 is alculated as:
I2 = ((Q − df )/Q) × 100. (1)
Q is Cochran’s heterogeneity statistic; df equals degrees of
freedom.
4 I2 lies between 0% and 100%: 0% indicates no observed
heterogeneity, greater than 50% considered substantial
heterogeneity.
5 Advantage of I2 : does not inherently depend on the number
of the studies.Extent of Heterogeneity
1 Assessed statistically using the quantity I2 described by
Higgins and Colleagues (2002).
2 Deﬁned as percentage of total variation across studies
attributable to heterogeneity rather than chance.
3 I2 is alculated as:
I2 = ((Q − df )/Q) × 100. (1)
Q is Cochran’s heterogeneity statistic; df equals degrees of
freedom.
4 I2 lies between 0% and 100%: 0% indicates no observed
heterogeneity, greater than 50% considered substantial
heterogeneity.
5 Advantage of I2 : does not inherently depend on the number
of the studies.Extent of Heterogeneity
1 Assessed statistically using the quantity I2 described by
Higgins and Colleagues (2002).
2 Deﬁned as percentage of total variation across studies
attributable to heterogeneity rather than chance.
3 I2 is alculated as:
I2 = ((Q − df )/Q) × 100. (1)
Q is Cochran’s heterogeneity statistic; df equals degrees of
freedom.
4 I2 lies between 0% and 100%: 0% indicates no observed
heterogeneity, greater than 50% considered substantial
heterogeneity.
5 Advantage of I2 : does not inherently depend on the number
of the studies.Extent of Heterogeneity
1 Assessed statistically using the quantity I2 described by
Higgins and Colleagues (2002).
2 Deﬁned as percentage of total variation across studies
attributable to heterogeneity rather than chance.
3 I2 is alculated as:
I2 = ((Q − df )/Q) × 100. (1)
Q is Cochran’s heterogeneity statistic; df equals degrees of
freedom.
4 I2 lies between 0% and 100%: 0% indicates no observed
heterogeneity, greater than 50% considered substantial
heterogeneity.
5 Advantage of I2 : does not inherently depend on the number
of the studies.Extent of Heterogeneity
1 Assessed statistically using the quantity I2 described by
Higgins and Colleagues (2002).
2 Deﬁned as percentage of total variation across studies
attributable to heterogeneity rather than chance.
3 I2 is alculated as:
I2 = ((Q − df )/Q) × 100. (1)
Q is Cochran’s heterogeneity statistic; df equals degrees of
freedom.
4 I2 lies between 0% and 100%: 0% indicates no observed
heterogeneity, greater than 50% considered substantial
heterogeneity.
5 Advantage of I2 : does not inherently depend on the number
of the studies.Sources of Heterogeneity: Meta-regression
1 There are diﬀerent sources of heterogeneity in meta-analysis:
characteristics of the study population, variations in the study
design (type of design, selection procedures, sources of
information, how the information is collected), diﬀerent
statistical methods, and diﬀerent covariates adjusted for (if
relevant)
2 Formal investigation of sources of heterogeneity is performed
by meta-regression, a collection of statistical procedures
(weighted/unweighted linear, logistic regression) in which the
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Publication bias Tendency for investigators, reviewers, and editors
to submit or accept manuscripts for publication
based on the direction or strength of the study
ﬁndings.
Funnel plot Exploratory tool for investigating publication bias,
plotting a measure of eﬀect size versus a measure
of study precision
1 Funnel plot should appear symmetric if no bias is present
2 Assessment of such a plot is very subjective.
3 Non-parametric and linear regression methods used to
formally test funnel plot asymmetry.Publication and Other Precision-related Biases
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(Begg 1994) Rank correlation between standardized eﬀect and
its standard error
(Egger 1997) Linear regression of intervention eﬀect against its
standard error weighted by inverse of the
variance of intervention eﬀect estimate
(Macaskill 2001) Linear regression of intervention eﬀect on sample
size
(Harbord 2006) Modiﬁed vesion of (Egger 1997) based on
”score” and ”score variance” of the log odds
ratio
(Peters 2006) Linear regression of intervention eﬀect on inverse
of sample sizeProblems with sample size and standard error
1 The asymptotic standard error is a biased estimate of the true
standard error, with larger bias for smaller cell sizes, as occurs
with larger DORs and smaller studies
2 Diagnostic studies have unequal sample sizes in diseased and
non-diseased groups which reduces the precision of an
estimate of test accuracy for a given sample size
3 The standard error of the logDOR depends on proportion
testing positive. However, individual studies often diﬀer in
positivity threshold leading to variability in proportion testing
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The most commonly used and easy to implement method
1 Linear regression analysis of the relationship
D = a + bS where :
D = (logit TPR) - (logit FPR) = ln DOR
S = (logit TPR) + (logit FPR) = proxy for the threshold
2 a and b may be estimated by weighted or unweighted least
squares or robust regression, back-transformed and plotted in
ROC space
3 Diﬀerences between tests or subgroups may examined by
adding covariates to model
Moses, Shapiro and Littenberg. Med Decis Making (1993)12:1293-1316Summary ROC Meta-analysis of Diagnostic Test Accuracy
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1 Assumes variability in test performance due only to threshold
eﬀect and within-study variability
2 Does not provide average estimates of sensitivity and
speciﬁcity
3 Continuity correction may introduce non-negligible downward
bias to the estimated SROC curve
4 Does not account for measurement error in S
5 Ignores potential correlation between D and S
6 Conﬁdence intervals and p-values are likely to be inaccurateSummary ROC Meta-analysis of Diagnostic Test Accuracy
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Publication Bias test for Diagnostic Meta-analysis
1 linear regression of log odds ratio on inverse square root of
eﬀective sample size
2 Uses the eﬀective sample size as weight
3 Eﬀective sample size=4*(ndis*nndis)/sample size
Bivariate Mixed Eﬀects Models
1 Focused on inferences about sensitivity and speciﬁcity but
SROC curve(s) can be derived from the model parameters
2 Generalization of the commonly used DerSimonian and Laird
random eﬀects model
Arends et al. Med Decis Making. Published online June 30, 2008Recent Developments
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Deeks’ Funnel Plot Asymmetry Test
pvalue  =   0.89
 Bivariate Linear Mixed Model



















pAi and pBi Sensitivity and speciﬁcity of the ith study
µAi and µBi Logit-transforms of sensitivity and speciﬁcity of the
ith study
Ci Within-study variance matrix
s2
Ai and s2
Bi variances of logit-transforms of sensitivity and
speciﬁcity
Reitsma JB et al. J. Clin Epidemiol (2005) 58:982-990Bivariate Linear Mixed Model



















µAi and µBi Logit-transforms of sensitivity and speciﬁcity of the
ith study
MA and MB Means of the normally distributed logit-transforms
ΣAB Between-study variances and covariance matrix
Reitsma JB et al. J. Clin Epidemiol (2005) 58:982-990Bivariate Binomial Mixed Model
Level 1: Within-study variability
yAi ∼ Bin(nAi,pAi)
yBi ∼ Bin(nBi,pBi)
nAi and nBi Number of diseased and non-diseased
yAi and yBi Number of diseased and non-diseased with true test
results
pAi and pBi Sensitivity and speciﬁcity of the ith study
Chu H, Cole SR (2006) J. Clin Epidemiol 59:1331-1332Bivariate Binomial Mixed Model
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1 Exact binomial approach preferred especially for small sample
data and for avoiding continuity correction
2 The relation between logit-transformed sensitivity and
speciﬁcity is given by µAi = a+b×µBi with slope b = σAB/σ2
A
and intercept a = MA - b×MB
3 SROC may be obtained after anti-logit transformation of the
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regression lineMethodological Framework
Propose a generalized framework for diagnostic meta-analysis
based on a modiﬁcation of the bivariate Dale model:
1 Univariate random-eﬀects logistic models for sensitivity and
speciﬁcity are associated through a log-linear model of odds
ratios with eﬀective sample size as independent variable
2 This uniﬁes the estimation of summary test performance and
assessment of the presence, extent, and sources of variabilityMethodological Framework
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Discuss speciﬁcation, estimation, diagnostics, and prediction of
model:
1 Using a motivating dataset of 43 studies investigating
FDG-PET for staging the axilla in patients with newly
diagnosed breast cancer
2 Taking advantage of the ability of gllamm to model a mixture
of discrete and continous outcomesMethodological Framework
Discuss speciﬁcation, estimation, diagnostics, and prediction of
model:
1 Using a motivating dataset of 43 studies investigating
FDG-PET for staging the axilla in patients with newly
diagnosed breast cancer
2 Taking advantage of the ability of gllamm to model a mixture
of discrete and continous outcomesBivariate Dale Model (Correlated Binary Responses)
1 Joint probabilities decomposed into two marginal distributions for
the main eﬀects




1 h1, h2, h3 are link functions in the GLM terminology
2 p1+ and p+1 are the marginal probabilities for response1=1 and
response2=1 respectively
3 Most popular choice for h1=h2 is the logit function
4 Commonly used link function for h3 is the natural logarithm:




nAi and nBi Number of diseased and non-diseased
yAi and yBi Number of diseased and non-diseased with true test
results




















µAi and µBi Logit-transforms of sensitivity and speciﬁcity of the
ith study
MA and MB Means of the normally distributed logit-transforms
ΣAB Between-study variancesModiﬁed Bivariate Dale Model
Association Model
Associates the univariate random-eﬀects logistic models for
sensitivity and speciﬁcity in the form a log-linear model:
logDORi = a+b×ESSi
intercept a = adjusted odds ratio
and slope b = bias coeﬃcientExample: PET for axillary staging of breast Cancer
1 PET or Positron Emission Tomography uses radiolabeled
glucose analog to evaluate tumor metabolism
2 This radiological test may be used to stage and/or examine
the extent of breast cancer
3 The accuracy of axillary PET has been studied by many
researchers
4 We obtained, by searching PUBMED, 43 studies published
between 1990 and 2008Example: PET for axillary staging of breast Cancer
1 PET or Positron Emission Tomography uses radiolabeled
glucose analog to evaluate tumor metabolism
2 This radiological test may be used to stage and/or examine
the extent of breast cancer
3 The accuracy of axillary PET has been studied by many
researchers
4 We obtained, by searching PUBMED, 43 studies published
between 1990 and 2008Example: PET for axillary staging of breast Cancer
1 PET or Positron Emission Tomography uses radiolabeled
glucose analog to evaluate tumor metabolism
2 This radiological test may be used to stage and/or examine
the extent of breast cancer
3 The accuracy of axillary PET has been studied by many
researchers
4 We obtained, by searching PUBMED, 43 studies published
between 1990 and 2008Example: PET for axillary staging of breast Cancer
1 PET or Positron Emission Tomography uses radiolabeled
glucose analog to evaluate tumor metabolism
2 This radiological test may be used to stage and/or examine
the extent of breast cancer
3 The accuracy of axillary PET has been studied by many
researchers
4 We obtained, by searching PUBMED, 43 studies published
between 1990 and 2008Example: PET for axillary staging of breast Cancer
Table: Dataset
Idnum Author Year TP FP FN TN SIZE
1 Tse 1992 4 0 3 3 10
2 Adler1 1993 8 0 1 10 18
3 Hoh 1993 6 0 3 5 14
4 Crowe 1994 9 0 1 10 20
5 Avril 1996 19 1 5 26 51
6 Bassa 1996 10 0 3 3 16
7 Scheidhauer 1996 9 1 0 8 18
8 Utech 1996 44 20 0 60 124
9 Adler2 1997 19 11 0 20 50
10 Palmedo 1997 5 0 1 14 20
11 Noh 1998 12 0 1 11 24
12 Smith 1998 19 1 2 28 50
13 Rostom 1999 42 0 6 26 74
14 Yutani1 1999 8 0 2 16 26
15 Hubner 2000 6 0 0 16 22
- - - - - - - -
- - - - - - - -
32 Wahl 2004 66 40 43 159 308
33 Zornoza 2004 90 2 17 91 200
34 Weir 2005 5 3 13 19 40
35 Gil-Rendo 2006 120 2 22 131 275
36 Kumar 2006 16 2 20 40 80
37 Stadnik 2006 4 0 1 5 10
38 Chung 2006 25 0 17 18 51
39 Veronesi 2006 38 5 65 128 236
40 Cermik 2008 40 15 39 125
41 Ueda 2008 34 6 25 118
42 Fuster 2008 14 0 6 32
43 Heuser 2008 8 0 2 20Recode Data for gllamm
gen dor = (tp*tn)/(fp*fn)
gen ldor = ln(dor)
gen ldorvar = (1/fn)+(1/tn)+(1/fp)+(1/tp)
gen ldorse = sqrt((1/fn)+(1/tn)+(1/fp)+(1/tp))
tempvar n1 n2 ESS zero thetai sethetai
gen ‘n1’ = tp + fn
gen ‘n2 ’= tn + fp
gen ‘ESS’ =(4 * ‘n1’ * ‘n2’)/(‘n1’ + ‘n2’)
gen ‘thetai’=(tp * tn)/(fp * fn)
replace ‘thetai’=log(‘thetai’)
gen ‘sethetai’=sqrt(‘ESS’)
gen size =1/‘sethetai’Recode Data for gllamm
gen ttruth1 = tn /* number truly disease-free */
gen ttruth2 = tp /* number truly diseased */
gen ttruth3 = ‘thetai’
gen num1 = tn+fp /* total disease-free */
gen num2 = tp+fn /* total diseased */
gen num3 = 1
reshape long num ttruth, i(study) j(dtruth) string




gen gvar = .
replace gvar = 1 if dtruth == "1"
replace gvar = 2 if dtruth == "2"
replace gvar = 3 if dtruth == "3"
forvalues i=1/3 {
g size_‘i’ = disgrp‘i’* size
}
}Bivariate Binomial Mixed Model
gllamm ttruth disgrp1 disgrp2 if dtruth !="3", nocons ///
i(study) nrf(2) eqs(disgrp1 disgrp2) ///
f(bin) l(logit) denom(num) ip(m) adapt
Table: Estimation results







Correlation -0.319 (0.256)Bivariate Binomial Mixed Model
Table: Summary estimates





lrn 0.297 (0.042)Forest Plot
SENSITIVITY (95% CI)
Q =286.37, df = 42.00, p =  0.00
I2 = 85.33 [81.61 − 89.06]
 0.72[0.63 − 0.79]
0.57 [0.18 − 0.90]
0.89 [0.52 − 1.00]
0.67 [0.30 − 0.93]
0.90 [0.55 − 1.00]
0.79 [0.58 − 0.93]
0.77 [0.46 − 0.95]
1.00 [0.66 − 1.00]
1.00 [0.92 − 1.00]
1.00 [0.82 − 1.00]
0.83 [0.36 − 1.00]
0.92 [0.64 − 1.00]
0.90 [0.70 − 0.99]
0.88 [0.75 − 0.95]
0.80 [0.44 − 0.97]
1.00 [0.54 − 1.00]
0.74 [0.49 − 0.91]
0.50 [0.25 − 0.75]
0.94 [0.86 − 0.98]
0.79 [0.62 − 0.91]
0.50 [0.12 − 0.88]
0.68 [0.43 − 0.87]
0.43 [0.18 − 0.71]
0.20 [0.01 − 0.72]
0.47 [0.21 − 0.73]
0.53 [0.27 − 0.79]
0.80 [0.56 − 0.94]
0.25 [0.11 − 0.43]
0.21 [0.05 − 0.51]
0.67 [0.09 − 0.99]
0.60 [0.42 − 0.76]
0.36 [0.18 − 0.57]
0.61 [0.51 − 0.70]
0.84 [0.76 − 0.90]
0.28 [0.10 − 0.53]
0.85 [0.77 − 0.90]
0.44 [0.28 − 0.62]
0.80 [0.28 − 0.99]
0.60 [0.43 − 0.74]
0.37 [0.28 − 0.47]
0.51 [0.39 − 0.62]
0.58 [0.44 − 0.70]
0.70 [0.46 − 0.88]



















































Q =245.64, df = 42.00, p =  0.00
I2 = 82.90 [78.37 − 87.44]
 0.96[0.93 − 0.97]
1.00 [0.29 − 1.00]
1.00 [0.69 − 1.00]
1.00 [0.48 − 1.00]
1.00 [0.69 − 1.00]
0.96 [0.81 − 1.00]
1.00 [0.29 − 1.00]
0.89 [0.52 − 1.00]
0.75 [0.64 − 0.84]
0.65 [0.45 − 0.81]
1.00 [0.77 − 1.00]
1.00 [0.72 − 1.00]
0.97 [0.82 − 1.00]
1.00 [0.87 − 1.00]
1.00 [0.79 − 1.00]
1.00 [0.79 − 1.00]
1.00 [0.75 − 1.00]
1.00 [0.85 − 1.00]
0.86 [0.78 − 0.93]
0.92 [0.84 − 0.97]
1.00 [0.74 − 1.00]
0.67 [0.30 − 0.93]
0.94 [0.71 − 1.00]
1.00 [0.69 − 1.00]
0.95 [0.76 − 1.00]
0.86 [0.64 − 0.97]
0.95 [0.75 − 1.00]
0.97 [0.86 − 1.00]
1.00 [0.81 − 1.00]
0.62 [0.38 − 0.82]
0.96 [0.85 − 0.99]
0.97 [0.89 − 1.00]
0.80 [0.74 − 0.85]
0.98 [0.92 − 1.00]
0.86 [0.65 − 0.97]
0.98 [0.95 − 1.00]
0.95 [0.84 − 0.99]
1.00 [0.48 − 1.00]
1.00 [0.81 − 1.00]
0.96 [0.91 − 0.99]
0.89 [0.83 − 0.94]
0.95 [0.90 − 0.98]
1.00 [0.89 − 1.00]














































































































SENS = 0.72 [0.63 − 0.79]
SPEC = 0.96 [0.93 − 0.97]
SROC Curve
AUC = 0.94 [0.92 − 0.96]
95% Confidence Contour
95% Prediction Contour
 No bias Uncorrelated Random-Eﬀects
gllamm ttruth disgrp1 disgrp2 disgrp3, nocons nocor ///
i(study) nrf(2) eqs(disgrp1 disgrp2) f(bin bin gauss) ///
l(logit logit id) denom(num) ip(m) adapt fv(gvar) lv(gvar)
Table: Estimation results







logitspe 1.143 (0.173)No bias Uncorrelated Random-Eﬀects
Table: Summary estimates





lrn 0.297 (0.041)Bias Correlated Random-Eﬀects
gllamm ttruth disgrp1 disgrp2 disgrp3 size_3, nocons ///
i(study) nrf(2) eqs(disgrp1 disgrp2) f(bin bin gauss) ///
l(logit logit id) denom(num) ip(m) adapt fv(gvar) lv(gvar)
Table: Estimation results









Correlation -0.319 (0.256)Bias Correlated Random-Eﬀects
Table: Summary estimates





lrn 0.297 (0.042)Bias Uncorrelated Random-Eﬀects
gllamm ttruth disgrp1 disgrp2 disgrp3 size_3, nocons nocor ///
i(study) nrf(2) eqs(disgrp1 disgrp2) f(bin bin gauss) ///
l(logit logit id) denom(num) ip(m) adapt fv(gvar) lv(gvar)
Table: Estimation results








logitspe 1.144 (0.173)Bias Uncorrelated Random-Eﬀects
Table: Summary estimates





lrn 0.297 (0.041)Comparative Results
Table: Fit and Complexity Measures
Model nparm Deviance BIC
No Bias 7 548.42 582.44
Bias Correlated Random-eﬀects 8 548.42 587.30
Bias Uncorrelated Random-eﬀects 7 548.37 582.39
Table: Sensitivity and Speciﬁcity
Model Sens Spec
No Bias 0.716 (0.638 - 0.795) 0.956 (0.935 - 0.978)
Bias Correlated RE 0.716 (0.638 - 0.795) 0.956 (0.935 - 0.978)
Bias Uncorrelated RE 0.715 (0.638 - 0.792) 0.958 (0.937 - 0.979)Prediction and Diagnostics





















































































































































1 The preferred model is the Bias Uncorrelated Random-eﬀects
Model
2 If interest is in diagnostic performance only, then the Bivariate
binomial mixed and modiﬁed bivariate Dale models are
equivalent.
3 The modiﬁed bivariate Dale models may be extended further to
include study-level covariates to assess impact on summary test
performance jointly or separately.Conclusions
1 The preferred model is the Bias Uncorrelated Random-eﬀects
Model
2 If interest is in diagnostic performance only, then the Bivariate
binomial mixed and modiﬁed bivariate Dale models are
equivalent.
3 The modiﬁed bivariate Dale models may be extended further to
include study-level covariates to assess impact on summary test
performance jointly or separately.Conclusions
1 The preferred model is the Bias Uncorrelated Random-eﬀects
Model
2 If interest is in diagnostic performance only, then the Bivariate
binomial mixed and modiﬁed bivariate Dale models are
equivalent.
3 The modiﬁed bivariate Dale models may be extended further to
include study-level covariates to assess impact on summary test
performance jointly or separately.